Home of Avontec
 
 
               
 
In AnGes MG, Avontec has a corporate partner and investor strongly aligned with Avontec's dual goals of successful drug development and business success. A leader in oligonucleotide therapeutics, AnGes MG is a public company listed on the Tokyo Stock Exchange, where it carried out an IPO in September, 2002.

Avontec and AnGes MG cooperate at both the operational as well as the strategic levels. A cross-licensing agreement underlines AnGes's strong financial and strategic commitment. Based on Avontec's core transcription factor-targeting decoy technology, both companies aim to establish the leading nucleic-acid based drug-developing platform in the area of novel anti-inflammatory therapeutics.

AnGes is developing decoy-based therapeutics in complementary but distinct areas of inflammatory disease. AnGes is also in multiple phase 2 and phase 3 clinical trials in other indication areas.
Avontec's cooperation with AnGes has created a wider investor base for Avontec as well as a stronger connection to the Asian market. These clinical and business links create an unusual advantage for Avontec compared to its European biotech company peers. Avontec expects to reap the benefits of these advantages in its upcoming clinical trials and corporate interactions.

With respect to the development of decoy-based anti-inflammatory drugs, both companies have successfully translated their preclinical projects into clinical development programs. Here, Avontec and AnGes MG perfectly complement each other and expect to realize valuable gains by creating strategic synergies in the near future.